Drug intelligence / Profile preview

Guben Qushi Huayu formula + ixekizumab

Development stage: Preclinical
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Subcutaneous

Overview

Guben Qushi Huayu formula (GQHF) combined with ixekizumab is a therapeutic approach being investigated for reducing psoriasis vulgaris (PV) relapse. Ixekizumab is recommended as a first-line therapy for severe PV but faces challenges with relapse after treatment discontinuation. GQHF is a Chinese herbal medicine that has demonstrated effectiveness in reducing PV relapse in clinical practice. The combination aims to provide a novel therapeutic option with improved efficacy in preventing relapse compared to ixekizumab alone.

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on Guben Qushi Huayu formula + ixekizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guben Qushi Huayu formula + ixekizumab.

Explore the full profile